Clinical Research Directory

Main Inclusion Criteria: 1. Age ≥ 18 years and ≤ 75 years at time of study entry. 2. Has histologically-confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix. 3. The International Federation of Gynecology and Obstetrics (FIGO) 2018 Stages III-IVA. 4. Diagnosed with PD-L1-positive (combined positive score ≥1). 5. Has not previously received any definitive surgical, radiation, or systemic therapy for cervical cancer. 6. WHO/ECOG performance status of 0 or 1. 7. Patient must have at least one measurable disease as defined by RECIST 1.1. Main Exclusion Criteria: 1. Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent o.. 2. Ongoing participation in another clinical study, or planned initiation of treatment in this study less than 28 days from the end of treatment in the previous clinical study. 3. Known history of serious allergy to any active ingredie or any excipients list in monoclonal antibody. 4. The patient has other factors that, in the judgment of the investigator, may lead to forced early termination of the study.